Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	48.66	57.42	68.18	117.87	29.34	20.43
Cash & Cash Equivalents	48.66	57.42	68.18	117.87	29.34	20.43
Cash Growth	-28.63%	-15.78%	-42.15%	301.79%	43.57%	-40.65%
Receivables	0	0	0	1.77	1.27	0.72
Other Current Assets	4.84	6.34	7.02	4.51	6.55	16.9
Total Current Assets	53.5	63.76	75.2	124.15	37.16	38.04
Property, Plant & Equipment	1.47	1.65	2.22	3.16	1.97	14.45
Goodwill and Intangibles	0.97	1.09	0	30.71	39.56	55.57
Total Long-Term Assets	2.44	2.74	2.22	33.87	41.53	70.02
Total Assets	55.94	66.5	77.41	158.02	78.68	108.06
Accounts Payable	2.46	2.35	3.49	3.12	4.17	7.94
Current Debt	5.29	0.65	13.89	0.78	0.8	22.16
Other Current Liabilities	3.26	6.49	6.99	11.78	5.75	7.25
Total Current Liabilities	11	9.49	24.38	15.68	10.71	37.35
Long-Term Debt	0.73	5.3	1.48	20.17	21.63	18.36
Other Long-Term Liabilities	1.37	1.18	0.16	12.17	65.07	2.03
Total Long-Term Liabilities	2.1	6.48	1.64	32.34	86.69	20.39
Total Liabilities	13.1	15.96	26.01	48.02	97.4	57.74
Total Debt	6.02	5.95	15.37	20.95	22.42	40.52
Debt Growth	-60.84%	-61.27%	-26.64%	-6.56%	-44.67%	50.88%
Retained Earnings	-428.58	-419.63	-404.58	-371.21	-387.12	-182.58
Comprehensive Income	-18.28	-17.49	-21.69	-0.43	-0.19	-0.62
Shareholders' Equity	42.84	50.54	51.4	110	-18.71	50.32
Net Cash / Debt	42.64	51.47	52.81	96.92	6.92	-20.09
Net Cash / Debt Growth	-19.26%	-2.54%	-45.51%	1301.34%	-	-
Net Cash Per Share	-	0.08	0.09	-	-	-
Working Capital	42.49	54.27	50.82	108.48	26.45	0.7
Book Value Per Share	0.31	0.38	0.43	1.01	-0.28	3.54

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).